At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based Founder operating in the Biotechnology space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Richard Terry
CEO, CTO and Founder of Harton Therapeutics
For more than 15 years, Richard Terry has led cross-functional teams in the development of innovative and novel technologies. His unique background in aerospace engineering, physics and biochemistry is a testament to his ability to transcend barriers and bring together a diverse set of resources to achieve the impossible. Richard’s research interests include applying systems-level engineering to biological challenges, and he is a prominent expert in synthetic biology. Prior to launching ReadCoor, Richard was Lead Senior Staff Scientist at Harvard University’s Wyss Institute for Biologically Inspired Engineering. At the Wyss, he supported advancements in reading, writing and editing nucleic acid, better known as nucleic acid sequencing, gene synthesis, and gene editing. Richard was one of the institute’s first hires and joined the founding team before the research center opened its doors. He built and transformed the Synthetic Biology group from its earliest form into the world-renowned Translational Synthetic Biology group that it is today. A sample of the tools developed by the Synthetic Biology group under his charge includes Ultra-Long DNAs, Next Gen Sequencing, Nanopore Sequencing, Multiplexed Automated Genome Engineering (MAGE), Programmable DNA Nanotherapeutic Robotic Device, CRISPR, TALEN, Zinc Finger, CADnano, SeqTag, Data Encoding and Enzymatic Synthesis of DNA.
Follow Richard Terry:
About Harton Therapeutics, Harvard Medical School: Harton is a biotechnology platform company pioneering the next revolution in personalized immune therapies to treat each and every patient.
_______
David Yu Zhang
Co-Founder & Head of Innovation of NuProbe
David Zhang, Ph.D., is the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. He is a leading expert in molecular diagnostics and DNA biotechnology, and maintains active collaborations with multiple biotech companies.
Follow David Yu Zhang:
About NuProbe: An early stage molecular diagnostics company.
Peng Yin
Co-Founder, Director of NuProbe
Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Co-Founder, Director at Torus Biosystems.
Follow Peng Yin:
About Harvard Medical School, NuProbe, Torus Biosystems, Ultivue, Wyss Institute: An early stage molecular diagnostics company.
Yingshuang Chai
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
Junfeng Luo
Co-Founder & Vice President, R&D – NuProbe, China of NuProbe
Junfeng Luo is a Co-Founder and Vice President of R&D at NuProbe, China.
Follow Junfeng Luo:
About NuProbe: An early stage molecular diagnostics company.
Yundi Chen
Co-Founder of NuProbe
Yundi Chen is a Co-Founder at NuProbe.
Follow Yundi Chen:
About NuProbe: An early stage molecular diagnostics company.
Gregory Winter
Scientific Founders of Bicycle Therapeutics
Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge and most of his scientific career was based there. He was Head of Division of Protein and Nucleic Acid Chemistry, succeeding Cesar Milstein and has served as both Deputy and Acting Director of the LMB. He is a Fellow of the Royal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge. Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing respectively and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies. He invented techniques to humanise rodent antibodies for use as therapeutics (1986–), working with H. Waldmann in the development of alemtuzumab/Campath-1H. Later, in competition with R. Lerner, he developed methods to make fully human antibodies (1989–) against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the US FDA. Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT,1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics. CAT was floated on the London Stock Exchange in 1997 and was responsible for the co-development of the therapeutic antibodies adalimumab/Humira and belimumab/Benlysta. CAT was acquired by AstraZeneca in 2006. Domantis developed a range of product leads based on single antibody domains and was acquired by GSK in 2006 in a private sale. Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (US) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008. In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.
Follow Gregory Winter:
About Ahren Innovation Capital, Bicycle Therapeutics, MRC Laboratory of Molecular Biology, Trinity College, Dublin: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Christian Heinis
Scientific Founders of Bicycle Therapeutics
Christian Heinis is Scientific Founders at Bicycle Therapeutics.
Follow Christian Heinis:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Paul Chang
President, CEO/CSO and Lead Founder of ARase Therapeutics
Follow Paul Chang:
About ARase Therapeutics: Arase Therapeutics is a science-focused oncology company developing therapies that modulate cancer-relevant cell signaling pathways.
Edwin Kania
Managing Partner & Co-Founder; Chairman Emeritus of Flagship Pioneering
Edwin Kania is a Managing Partner and Co-Founder of Flagship Ventures and served as Chairman of the Board of Directors at Flagship Ventures between 2001 – 2014. Edwin has 33 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, Edwin spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983 – 1984 Edwin served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston and previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. Edwin is a frequent speaker on venture capital and entrepreneurship. Edwin earned his undergraduate degree in Physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, Edwin was an All-American Track and Field athlete and a national and collegiate record holder. Throughout his professional career, Edwin has operated both as an investor and as an active partner to entrepreneurs in company building. Edwin’s direct investment experience covers over 100 companies. In addition, Edwin has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Acceleron Pharma (NASDAQ: XLRN), Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp). Currently, Edwin is a Director of Flagship portfolio companies EcoSense Lighting, Oasys Water, Selecta Biosciences, TARIS Biomedical, Tarveda Therapeutics, TransMedics and Visterra, as well as on the Board of DataCore Software. Edwin also serves on the Board of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. Edwin has been a long-time Member of the Board of Directors of MassBio, a not-for-profit organization representing theMassachusetts biopharmaceutical industry and serves as a Member of Harvard Partners’ Innovation Advisory Board and The Johns Hopkins Medicine Alliance for Science and Technology Development.
Follow Edwin Kania:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Noubar Afeyan
Founder & CEO of Flagship Pioneering
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm’s VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
Follow Noubar Afeyan:
About BIND Therapeutics, Cogen Therapeutics, Cygnal Therapeutics, Ensemble Therapeutics, Flagship Pioneering, Generate Biomedicines, Harvard Business School, Indigo, Joule Unlimited Technologies, Laronde, Massachusetts Institute of Technology, Moderna Therapeutics, Omega Therapeutics, Permeon Biologics, Ring Therapeutics, Rubius Therapeutics, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Nichola Eliovits
Co-Founder, Chief Business Officer of DermBiont
Nick’s investment expertise spans across asset classes with an extensive focus on microbiome oriented companies across all stages of venture capital. Nick is a Managing Partner at Olive Tree Capital; he led his last company through acquisition and has successfully seeded and structured companies across multiple industries. His passion for the Microbiome originates from personal experiences with skin infections and c-diff. Nick graduated with honors from Boston University’s Questrom School of Business and started his career in commodity markets at CPM Group in New York.
Follow Nichola Eliovits:
About DermBiont, Popover: DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.
Lanny Sun
Co-Founder & CEO of Silicon Therapeutics
Follow Lanny Sun:
About Silicon Therapeutics: Silicon Therapeutics is a fully integrated drug design, research, and development company.
Geraldine Harriman
CSO & Co-Founder of HotSpot Therapeutics
Geraldine Harriman is the Co-Founder and Chief Scientific Officer of HotSpot Therapeutics.
Follow Geraldine Harriman:
About HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Nessan Bermingham
Founder, CEO & currently Exec Chair of Triplet Therapeutics
Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chair of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner. Nessan is co-founder and was previously chief executive officer of Intellia Therapeutics. He led Intellia from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
Follow Nessan Bermingham:
About Korro Bio, Triplet Therapeutics: Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Alexis Borisy
Co-Founder of Blueprint Medicines
Alexis Borisy is the Chairman of the Board of Directors & Co – Founder of Foundation Medicine Inc.He is also a Partner at Third Rock Ventures.Alexis Borisy is a successful biotechnology entrepreneur with 20 years of experience building and operating innovative science-based organizations. Alexis Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He co-founded Foundation Medicine and served as the company’s interim CEO through May 2011.Prior to joining Third Rock Ventures, Alexis Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis Borisy was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.Alexis Borisy’s Undergraduate Degree in Chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Alexis Borisy serves on the Board of the Biotechnology Industry Organization, is an Overseer at the Boston Museum of Science, is the Chairman of Forma Therapeutics, and serves on the board of Blueprint Medicines.
Follow Alexis Borisy:
About Blueprint Medicines, Blueprint Medicines, EQRx, Third Rock Ventures: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Nick Lydon
Scientific Founder of Blueprint Medicines
Nick Lydon, Ph.D., is a scientific founder of Blueprint Medicines. Before founding his current consulting company, Granite Biopharma, LLC, Dr. Lydon served as vice president, small molecule drug discovery at Amgen. Prior to joining Amgen, he founded and led Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, a number of which are now advancing through clinical development. Kinetix was acquired by Amgen in 2000. Prior to Kinetix, Dr. Lydon worked at CIBA-GEIGY, in Basel, Switzerland, where he was responsible for the protein kinase inhibitor program. He and his team identified a number of protein kinase inhibitors. The most advanced drug from this program is Gleevec®, a selective Bcr-Abl inhibitor for the treatment of chronic myelogenous leukemia (CML). Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation, where his research involved studies on recombinant alpha, beta and gamma interferons. In 2009, Dr. Lydon was awarded the Lasker-DeBakey Award for Clinical Medical Research for his work on developing Gleevec®, converting a fatal cancer into a manageable chronic condition. Other awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award, and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation for his contributions to the discovery and development of Gleevec®. Dr. Lydon earned a B.S. in biochemistry from the University of Leeds, England, and received his Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. His thesis involved research work on adenylate cyclase and cAMP dependent protein kinase. Dr. Lydon served as an advisor and member of the board of directors of Ambit BioScience from 2004 to 2009 and assisted in the development of AC220, a FLT3 kinase inhibitor in Phase 2 clinical development in relapsed/refractory acute myeloid leukemia (AML).
Follow Nick Lydon:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Mirza Cifric
Co-Founder & Chief Executive Officer of Veritas Genetics
Follow Mirza Cifric:
About Veritas Genetics, YPO: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Jonathan Zhao
Founder & Managing Director, Asia of Veritas Genetics
Jonathan Y. Zhao, Ph.D. is Co-Founder of Veritas Genetics and serves as its Managing Director of Asia. Jonathan Zhao is responsible for Asia strategy and new products at Amgen and Pfizer. He holds MBA from MIT Sloan and Ph.D. in Chemistry.
Follow Jonathan Zhao:
About Veritas Genetics: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Anna Villarreal
Founder & CEO of LifeStory Health Inc
Leading the first-ever discovery research into the clinical utility of menstrual blood, a recent Proof of Principle study resulted in findings of unique signatures specific to menstrual blood. On-going clinical studies aim to develop the diagnostic science further in order to support our preliminary pipeline. Anna’s resourceful leadership style and entrepreneurial experience has lead LifeStory Health, Inc. through remarkable discoveries and growth in a very short time when compared to most bioscience companies. She attributes this to her steadfast passion for and about Women’s Health. A strong advocate for women’s healthcare, Anna’s pioneering vision to map the menstrual blood proteome through a set of resolute, data-leading principles and an award winning scientific methodology has led to biomarker discovery based on precision medicine. Anna guest lectures for several graduate level programs at Northeastern University including data analytics, chemistry, regulatory affairs, and master’s in business administration. She teaches her own class in the Master’s of Biotechnology Program titled “Women’s Health: Driving Innovation and Cultural Change”. Her advocacy for women’s health continues on her podcast, “Setting the Pace”, in which she and her co-host highlight fellow female innovators.
Follow Anna Villarreal:
About CEOWORLD Magazine, LifeStory Health Inc, NEFC, The Doctor Weighs In: LifeStory Health is a biotech company committed to changing the women’s healthcare market through technology, innovation and vocalization.
Otello Stampacchia
Founder of Omega Funds
Otello Stampacchia is a partner at Omega Funds where he has had particular recent involvement in investments in Micromet, BioVex, Juno and Jounce Therapeutics. Previously, Otello was in charge of life sciences direct investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. At AlpInvest, Otello was responsible for the direct life sciences investments, as well as assisting in due diligence for healthcare venture fund of funds investments. Before AlpInvest, Otello was the portfolio manager of the Lombard Odier Immunology Fund, a $3bn listed investment vehicle, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before joining Goldman, Otello helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva (Switzerland), and a PhD in Biotechnology.
Follow Otello Stampacchia:
About Omega Funds: Omega Funds global life sciences-based investment firm specialized in direct secondary transactions.
Nick Davis
Founder, President, and Chief Executive Officer of Theonys
Nick Davis is the Founder, President & Chief Executive Officer of Theonys — a therapeutics company developing new small-molecule medicines to selectively stop the translation of disease-causing proteins in cancer, chronic inflammation and other serious human diseases.
Follow Nick Davis:
About Massachusetts Institute of Technology, Theonys: Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Stephen Smith
Co-Founder of Pear Therapeutics
Stephen Smith received his B.A from Harvard University, J.D. from Columbia University, and M.Ed from Harvard University School of Education. After law school, Stephen served as an assistant district attorney in New York. He later joined the staff of the Senate Judiciary and Foreign Relations Committees. After leaving the Senate, Stephen worked at Conflict Management Group; a nonprofit associated with Harvard Law School, and taught in the advanced program on negotiation at Harvard University Law School. As part of his work at Conflict Management, Stephen consulted with global clients including the Organization of African Unity, the World Bank, the Inter-American Development Bank and the parties in the Irish Peace process. Stephen is a three-time recipient of the Danforth Award for excellence in teaching at Harvard University and is also the winner of the Lyndehurst Foundation Prize for social and artistic achievement. For the past twenty years, Stephen has been on the Kennedy board of Joseph P. Kennedy Enterprises, the Kennedy family investment office. He has delivered keynote presentations at the annual conferences of the Family Firm Institute and the Family Office Exchange– the two major family business organizations. Stephen has also served on the board of the John F. Kennedy Library, the Robert F. Kennedy Memorial, Citizens Energy, the Northeastern University School of Public Policy, and INCAE Business School and the advisory board of the Joslin Diabetes Center at Harvard Medical School. Stephen is a Fellow at the International Economic Alliance, an organization dedicated to promoting innovative international trade. As a partner and board member, Stephen is actively involved in a number of medical and green technology businesses, including Emlink, which develops, designs and manages sustainable technology; The Marwood Group, a healthcare-focused strategic advisory and financial services firm; and Pear Therapeutics, a medical software company. Stephen was Deputy Campaign Manager for Senator Edward Kennedy during his Presidential and Senatorial campaigns, Youth Coordinator for the campaign of Mario Cuomo, served on the New England Steering Committee for the Obama presidential campaign, and continues to be active in Democratic politics.
Follow Stephen Smith:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Greg Verdine
Co-Founder, President & CEO, CSO of LifeMine Therapeutics
Greg Verdine is the Founder of Gloucester Marine Genomics Institute & he attended Massachusetts Institute of Technology in 1986.
Follow Greg Verdine:
About FogPharma, Gloucester Marine Genomics Institute, Harvard Medical School, Harvard University, LifeMine Therapeutics, Massachusetts Institute of Technology, Wave Life Sciences: Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology.
Philippe Leboulch
Founder & Co-Chair of Scientific Advisory Board of Bluebird Bio
Head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; Professor of Medicine, University of Paris; and Visiting Professor, Harvard Philippe Leboulch is a scientific founder of bluebird bio. He serves as the co-chairman of its Scientific Advisory Board and leader of the LentiGlobin® project. He is a professor of medicine and cell biology at the University of Paris and visiting professor at Harvard Medical School. Philippe is also the director of the Institute of Emerging Diseases and Innovative Therapies of the CEA near Paris and director of an INSERM research unit. He maintains a research laboratory in the genetics division of the Brigham & Women’s Hospital at Harvard Medical School, where he previously served as a full-time faculty member for 15 years after a postdoctoral fellowship at MIT. Philippe is an expert in vectorology and hematopoietic gene therapy, with special emphasis on the beta-hemoglobinopathies. He has been published extensively in high-impact journals and is a regularly invited speaker at major international conferences. Philippe was a member of the Editorial Board of Blood, the Journal of the American Society of Hematology. He has served on major committees of the National Institutes of Health and the American Society of Gene Therapy. Philippe has received numerous NIH grant awards and prizes that include the Grand Prize Etancelin of the French National Academy of Sciences.
Follow Philippe Leboulch:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
George Church
Founder of Gen9
George Church is a leading expert in human genetics and biotechnology.He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT).He is also director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. Church helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. Church pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. Church has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008. Church holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.A. in zoology and chemistry from Duke University.
Follow George Church:
About 64x Bio, ALACRiS Theranostics, digiD8, Editas Medicine, EGenesis, enEvolv, Fitbiomics, Gen9, GRO Biosciences, Harvard Medical School, Harvard Medical School, Harvard Medical School, Joule Unlimited Technologies, Kern Systems, Knome, Knome, LS9, Massachusetts Institute of Technology, Massachusetts Institute of Technology, Nebula Genomics, ReadCoor, ReadCoor, Tierra Biosciences, Inc.: Gen9 provides gene synthesis technology that enables the high-throughput, automated production of DNA constructs.
Amy Schulman
Executive Chairman & Co-Founder of Lyndra Therapeutics
Amy Schulman is the Chief Executive Officer at Arsia Therapeutics since August 2014. Arsia, a biotechnology company focused on improving patients’ lives through new modes of drug delivery, and a venture partner at Polaris, a leading venture capital firm with approximately 4 billion under management in August of 2014. Amy joined Polaris Partner’s Boston office as a Healthcare Venture Partner in 2014, simultaneously assuming the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company. In July 2015 Amy co-founded Lyndra where she is Chief Executive Officer and President. Amy is an accomplished business leader, widely recognized for growing and stabilizing global businesses, commitment to people, strategic judgment, and efforts to advance women and promote inclusive workplace cultures. Amy joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014. Prior to that, Amy led Pfizer Inc.’s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum and Chapstick. Amy also served as Executive Vice President and General Counsel of Pfizer Inc. Key accomplishments include: revitalization of the ChapStick brand; regulatory filing for Lipitor OTC; rapid growth of Emergen-C and increased Europe profitability. Amy originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth, the largest pharmaceutical acquisition in history. In 2009, Amy spearheaded an innovative approach to engaging outside counsel and became recognized as a leading voice for transforming the billable-hour model and for redefining the value of legal services. Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a Member of the Board and Executive Policy Committees and built and led the international law firm’s mass tort and class-action practice handling some of the most complex legal, scientific and regulatory challenges facing the world’s largest and most reputable companies, including Kraft, Altria, Cisco, GE Healthcare and Pfizer. Amy began her career in litigation with Cleary Gottlieb Steen & Hamilton. Amy’s accomplishments have earned her accolades from leading publications and organizations. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” Amy also has been recognized by The American Bar Association, which honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. In 2009 Forbes magazine included her on its inaugural list of “The World’s Most Powerful Women.” Amy serves on the Boards of Directors of Alnylam Pharmaceuticals, Arsanis, Biosciences, Arsia Therapeutics, BIND Therapeutics, Blue Buffalo, Lyndra, and SQZ Biotech. A Phi Beta Kappa Graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.
Follow Amy Schulman:
About Arsia Therapeutics, Harvard Business School, Lyndra Therapeutics, Polaris Partners, Suono Bio: Lyndra Therapeutics is a novel technology platform reinventing medicine for a healthier world.
Joseph Jacobson
CSO & Co-Founder of DeepCure
Joseph Jacobson is Associate Professor at the Massachusetts Institute of Technology (MIT) where he is co-PI of the Center for Bits and Atoms and leads the Molecular Machine Group. His group at MIT is focused on pioneering the field of Avogadro Scale Engineering with applications in novel computing machines and synthetic biology. Jacobson received his PhD in Physics from MIT and was a post-doctoral fellow at Stanford in the area of Quantum Optics. He is the recipient of a 1999 Technology Review TR100 Award for Innovation, The 2000 Gutenberg Prize and a 2001 Discover Award. He has authored over 70 peer reviewed papers and conference proceedings in the fields of femotosecond lasers, quantum optics, molecular electronics, nano-chemistry and synthetic DNA. In the private sector Jacobson was co-founder of E Ink, Kovio and Gen9 and was a founding board member of One Laptop Per Child (OLPC) which is focused on developing a $100 laptop for kids.
Follow Joseph Jacobson:
About DeepCure, E Ink, Kovio, Massachusetts Institute of Technology, Massachusetts Institute of Technology: DeepCuris builds an AI engine for small-molecule drug discovery.
Kfir Schreiber
Co-Founder & CEO of DeepCure
Kfir Schreiber is the CEO and Co-Founder of at DeepCure.
Follow Kfir Schreiber:
About DeepCure: DeepCuris builds an AI engine for small-molecule drug discovery.
Kristin Brief
Co-Founder and COO of Virex Health
Follow Kristin Brief:
About Virex Health: Virex is a biotechnology firm that enables widespread testing in life, homes, workplaces, schools, and public spaces globally.
Christoph Westphal
Founder & Executive Chairman of Verastem Oncology
Christoph Westphal is the Co-Founder, Chairman & Board Member at ImmuneID.
Follow Christoph Westphal:
About ImmuneID, Longwood Fund, Longwood Fund, Verastem Oncology: Verastem is a biopharmaceutical company that focuses on discovering and developing novel drugs that selectively target cancer stem cells.
Richard Friesner
Co-Founder of Schrödinger
Richard A. Friesner is Professor of Chemistry at Columbia University and Director of the Columbia Center for Biomolecular Simulation. He is a member of the National Academy of Sciences and American Academy of Arts of Sciences, and has been awarded a Sloan Foundation Fellowship, Camille and Henry Dreyfus Teacher-Scholar Award, and an NIH Research Career Development Award. Current interests include quantum chemistry, development of potential functions for molecular simulation, continuum electrostatic models, and protein folding. Dr. Friesner is a co-founder of Schrödinger, and a member of Schrödinger’s Board of Directors.
Follow Richard Friesner:
About Columbia University, Schrödinger: Schrödinger develops a chemical simulation software for use in pharmaceutical and biotechnology research.
Robert Nicol
Co-Founder of HiFiBiO
Rob Nicol is director of the Technology Labs at the Broad Institute of MIT and Harvard. Under Rob’s guidance, the Technology Labs serve as an advanced R&D group within the institute integrating capabilities in molecular biology, bio-engineering, synthetic biology, microfluidics, bio-informatics, and industrial process design to meet the needs of the Broad community. Rob is also co-founder of the MIT-Broad Foundry for Synthetic Biology. Rob joined the Whitehead Institute / MIT Center for Genome Research in 2001 to apply industrial process design to genome sequencing and directed the Sequencing Operations and Technology Development groups at the Broad for over 12 years, designing and implementing multiple generations of high-throughput DNA sequencing processes. Earlier, as an MIT Leaders for Manufacturing Fellow, Rob worked on production line optimization for Raytheon’s AMRAAM missile and Boeing’s 777. Rob previously worked as a project manager for Fluor Corporation, where he managed multiple, large-scale petrochemical design and construction projects. Rob received his B.S. in mechanical engineering from the University of Houston, and an M.S. in chemical engineering, M.B.A., and Ph.D. in engineering systems from MIT.
Follow Robert Nicol:
About HiFiBiO: HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
Allen Lin
Co-Founder and CSO of Oncolinx
Follow Allen Lin:
About Harvard University, Oncolinx: Oncolinx is developing antibody-drug conjugates.
Giulio Ruffini
President, CSO and co-founder of Neuroelectrics
Dr. Giulio Ruffini is the CEO and CTO of Starlab and the president and CSO of Neuroelectrics. He obtained a BA in Mathematics & Physics from Berkeley and a PhD in theoretical physics from UC Davis/LANL in 1995. In 2000 he founded Starlab to transform science into high-impact technologies.
12 years later he founded Neuroelectrics, a company which combines high-precision multichannel stimulation technologies with advanced biophysical and neuro-computational models.
For the past 15 years, Giulio has been developing technology for and researching the use of non-invasive brain monitoring and brain stimulation techniques, with a focus on EEG and transcranial current stimulation. His paper on brain-to-brain telepathy communication was the top 10 most shared papers of 2014. He is currently leading or involved in several European programs such as Galvani ERC Synergy, STIPED or Neurotwin.
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders with personalized neuromodulation, and improves overall brain health.
Thomas Schuetz
Co-Founder of Audentes Therapeutics
Dr. Schuetz, M.D., Ph.D., is the co-founder of Audentes Therapeutics and has served as a member of the board of directors since July 2013. Dr. Schuetz also provided consulting services to Audentes from July 2012 to June 2013. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed. Dr. Schuetz served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has also served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz also serves on the board of directors of Relypsa, Inc. and Glypharma, Inc. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.
Follow Thomas Schuetz:
About Audentes Therapeutics, Compass Therapeutics, Inc.: Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Venky Soundararajan
Co-Founder & Chief Scientific Officer of nference
Follow Venky Soundararajan:
About nference: nference.inc, provides an AI based software platform that synthesizes siloed biomedical knowledge for insights and makes it computable.
Gaurav Kaushik
Founder of Cascade.bio
Follow Gaurav Kaushik:
About Cascade.bio, ScienceIO: Cascade is rethinking how we interface with biomedical information, to accelerate therapeutic and clinical workflows.
Lara Yuan
Founder of Cascade.bio
Follow Lara Yuan:
About Cascade.bio: Cascade is rethinking how we interface with biomedical information, to accelerate therapeutic and clinical workflows.
George Hillman
COO, VP & Co-Founder of Viracta Therapeutics
George Hillman is the Co-Founder, Chief Operating Officer, and Vice President of Viracta Therapeutics.
Follow George Hillman:
About Viracta Therapeutics: Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.
Ignacio Martinez
Co-Founder, Chairman of the Board of Senda Biosciences
Ignacio Martinez is the Chairman of the Board and Co-Founder of Senda Biosciences. He joined Flagship Ventures in 2013 and focuses on sustainability and life sciences investments with a special interest in the agricultural sector. Ignacio holds a BS in Economics and Business Administration from Deusto University in Spain, and an International MBA from Instituto de Empresa in Spain, and WHU Otto Beisheim School of Management in Germany. Prior to joining Flagship, Ignacio was the Managing Director of Syngenta Ventures, where he was directly involved in investments in the agribusiness, biotechnology, and cleantech industries in Europe, North America, and Latin America. Syngenta Ventures is the venture capital arm of Syngenta International AG, the world’s largest agrochemical business with more than $13 billion in revenue. Ignacio has international board experience having served as Director in companies from seven different countries. He was also involved in corporate venture capital activities managing the relationship as a limited partner with Life Science Partners BioVentures, a $100 million Agribusiness fund, and the Gilde European Food and Agribusiness, a €90 million fund. Prior to Syngenta, Ignacio was the Chief Financial Officer of Progenika Group, where he was responsible for financial systems controls, transactions, and processes (GAAP/IFRS) reporting to the investors. He also oversaw spinoffs and M&A activity, participated in raising more than $50 million in funding, and actively participated in the expansion of the company to the US and Latin American markets. Before Progenika, Ignacio spent several years working for Najeti Ventures Fund investing in IT and biotech companies in Europe.
Follow Ignacio Martinez:
About Flagship Pioneering, Invaio Sciences, Senda Biosciences: Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
John Casey
Co-Founder, Vice President, Head of Business Development of Senda Biosciences
John is the Co-Founder, Vice President, and Head of Business Development of Senda Biosciences. Before that, he joined Flagship Pioneering in 2015 as an associate after completing the VentureLabs Fellows program. At Flagship, John works as part of a venture creation team, exploring innovative ideas and opportunities, and developing critical scientific and business components that will lead to the firm’s next breakthrough startups. Before joining Flagship, John earned his doctorate in biological engineering in Angela Belcher’s lab at MIT, where he designed and developed thermostable de novo enzymes on viral capsid proteins. His work led to a collaboration with the pharmaceutical industry to develop cleaner, more versatile manufacturing processes. John was an active contributor to Boston’s entrepreneurial community while a graduate student. As associate director for MIT’s $100K Entrepreneurship Competition, he partnered with local and national businesses to raise the competition’s six-figure annual budget. He developed a new prototyping contest with increased resources and direct support for student entrepreneurs. He subsequently served as Chair of the $100K’s board of directors. Additionally, John was a communication fellow in the Biological Engineering Department and served as the biotechnology editor for the MIT Entrepreneurship Review. John received his B.S. in biological engineering from Louisiana State University, where he was a Goldwater Scholar and named the top graduating student in his class. His thesis research explored site-specific oligonucleotide modifications. John was active in LSU’s Student Government, president of the campus Habitat for Humanity chapter, and a co-founder and president of an organization for Mandarin Chinese speakers.
Follow John Casey:
About Senda Biosciences: Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Jen Nwankwo
Founder, CEO of 1910 Genetics
Jen Nwankwo is the Founder and CEO at 1910 Genetics.
Follow Jen Nwankwo:
About 1910 Genetics: 1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development.
Suresh Jain
Co-Founder, President & COO of Acylin Therapeutics
Follow Suresh Jain:
About Acylin Therapeutics: Acylin Therapeutics operates in the pharmaceutical and drug manufacturing industry developing inhibitors of cellular acetylation.
David Heller
Co-Founder of C16 Biosciences
David Heller is a Co-Founder at C16 Biosciences.
Follow David Heller:
About C16 Biosciences: C16 Biosciences produces clean, safe alternatives to palm oil.
Harry McNamara
Co-Founder and CSO of C16 Biosciences
Harry McNamara is the Co-Founder and CSO at C16 Biosciences.
Follow Harry McNamara:
About C16 Biosciences: C16 Biosciences produces clean, safe alternatives to palm oil.
Alec Nielsen
Founder & CEO of Asimov
Alec Nielsen is the Founder & CEO at Asimov.
Follow Alec Nielsen:
About Asimov: Asimov builds tools to program living cells.
Alan D’Andrea
Co-Founder of Cedilla Therapeutics
Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response to DNA damage, with a particular focus on the pathogenesis of human chromosome instability and the identification of novel interacting proteins. Alan is a graduate of Harvard Medical School and a member of the National Academy of Medicine.
Follow Alan D’Andrea:
About Cedilla Therapeutics, Dana-Farber Cancer Institute: Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Raghu Kalluri
Scientific Founder of Codiak Biosciences
Raghu Kalluri is Chairman and Professor of the Department of Cancer Biology and the Director of the Metastasis Research Center at The University of Texas MD Anderson Cancer Center, where he also holds the Rebecca and Joseph Brown Endowed Chair. CPRIT funding helped bring Raghu Kalluri to Texas from Harvard Medical School in 2012. Raghu Kalluri received his Ph.D. in Biochemistry and Molecular Biology from the University of Kansas Medical Center and his M.D. degree from Brown University Medical School. He was a postdoctoral fellow and a research associate at the University of Pennsylvania Medical School and performed research in areas of immunology and organ fibrosis. In 1997, he moved to Harvard Medical School as an Assistant Professor of Medicine and as a faculty based in the Department of Medicine at the Beth Israel Deaconess Medical Center. Subsequently, Kalluri was appointed the Chief of the Division of Matrix Biology and promoted to Professor of Medicine at Harvard Medical School. He held appointments in the Department of Biological Chemistry and Molecular Pharmacology at HMS, Harvard MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute and was a research fellow of the HMS Peabody Society. Kalluri has trained more than 70 postdoctoral fellows and 20 graduate students in his career. He is a fellow of American Society of Clinical Investigation and the American Association for the Advancement of Science. In addition, Kalluri serves on science and health advisory panels in the U.S. and European Union and on the editorial boards of several academic journals representing biology and medicine.
Follow Raghu Kalluri:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Jo Viney
Co-Founder, President and Chief Scientific Officer of Pandion Therapeutics
Follow Jo Viney:
About Pandion Therapeutics: Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Kuldeep Singh Rajput
Founder & CEO of Biofourmis
Kuldeep Singh Rajput is the CEO and Founder of Biofourmis, a fast-growing digital health company filled with committed, passionate people who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. Biofourmis is pioneering an entirely new category of digital health, by developing clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Recognized as the “Forbes 30 Under 30”, Kuldeep has demonstrated strong leadership experience with building teams, developing talents, and successfully growing, and managing strategic partnerships with global pharmaceutical manufacturers, health systems and Payers. Under his leadership, Biofourmis has raised over US$45 Million in venture capital from leading Venture Capital firms including Sequoia Capital, MassMutual Ventures, Singapore Govt-linked EDBI, Aviva plc, and Mayo Clinic Ventures. He uses his background and experience in biomedical engineering and data from the Massachusetts Institute of Technology (MIT) to unfold his vision of “Predicting and Preventing Serious Medical Events using AI”. During his Ph.D. studies at the National University of Singapore (NUS), he built bioelectronic implants, which aim to control biological processes and treat diseases by modulating electric impulses. He believes in giving back and is part of the Milken Institute Young Leaders Circle (YLC), supporting the mission of providing people access to education and healthcare for stable economic growth. Kuldeep has been featured in major publications and has been a keynote speaker at numerous prestigious conferences like TED. Specialties: Entrepreneur, Fund Raising, Building Companies, Digital Therapeutics, Licensing, and Deal Structure, Healthcare Strategy, Digital Healthcare, Wearable Biosensors, Pharmaceuticals
Follow Kuldeep Singh Rajput:
About Biofourmis: Biofourmis is a biotechnology company that augments personalized care and therapies using digital therapeutics.
Paul Holzer
CEO and Co-Founder of XenoTherapeutics
Paul Holzer serves as CEO and co-founder of XenoTherapeutics. He is a scientist, engineer, and entrepreneur with over fifteen years of experience in various leadership and team management roles, and most recently in the fields of scientific research and new venture formation. Prior to founding XenoTherapeutics, Paul served as an Officer in the United States Navy SEAL Teams, with four decorated combat deployments to theatres such as Iraq, Afghanistan, and other undisclosed locations. He left the Navy in 2013 as a Lieutenant Commander (0-4) in the USNR.
Follow Paul Holzer:
About XenoTherapeutics: XenoTherapeutics is a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs.
Chen Schor
Co-Founder, President & CEO of resTORbio
Schor is a global healthcare industry leader with vast experience in pharmaceuticals, biotechnology, medical devices, business development and private equity. Schor has supported and helped build multiple healthcare companies and led multiple licensing, partnerships and M&A transactions with total value exceeding $8 billion with companies such as GSK, Amgen, Pfizer, Bayer, Teva and EMD-Serono. Prior to joining Novalere, Schor was VP Global Business Development with Teva Pharmaceuticals and had leadership roles at several emerging pharmaceutical and biotechnology companies. Schor was also a Partner at Yozma venture capital where he led the foundation and growth of multiple companies from inception to significant commercial success. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics, and is also a Certified Public Accountant (CPA).
Follow Chen Schor:
About Novalere FP, Predix Pharmaceuticals, resTORbio, Synta Pharmaceuticals: resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.
David Steinberg
Co-Founder of resTORbio
David Steinberg is currently a Venture Partner at Longwood Fund. He was formerly the Chief Innovation Officer at PureTech Health. As a member of PureTech Health, Mr. Steinberg led the development of a number of programs, including Vedanta Biosciences, Calix and Vor Biopharma. He also co-founded resTORbio during his tenure at PureTech Health. Previously, Mr. Steinberg was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology clients. Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals’ R&D organization. He received his BA in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Booth School of Business with an MBA in Strategy and Finance.
Follow David Steinberg:
About Be Biopharma, PureTech Health, Pyxis Oncology, resTORbio: resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.
Jean Sommadossi
Founder & Chief Executive Officer of Idenix Pharmaceuticals
Jean-Pierre Sommadossi is a veteran in the field of biotechnology. Jean Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc (NASDAQ: IDIX) and a co-Founder of Pharmasset, Inc (NASDAQ: VRUS), and served as Chairman and Chief Executive Officer of Idenix Pharmaceuticals from November 2000 to November 2010. From 1998 to November 2000, Jean Sommadossi has served as Chairman of the Board of Directors and then as Executive President and Chief Scientific Officer. Under his leadership, Idenix has raised more than $450 million in private and public equity financings and entered into multiple strategic partnerships, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotechpharma transaction with Novartis Pharma AG in 2003. Prior to founding Idenix, Jean Sommadossi was on the Faculty of The University of Alabama at Birmingham School of Medicine since March 1985. He has served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology as well as an Associate Director of both the Center for AIDS Research and The Liver Center from June 1992 to November 2000. Jean Sommadossi has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of Cancer and Infectious Diseases. Jean Sommadossi has earned his Pharm.D. and Ph.D. in Pharmacology degrees from the University of Marseilles in France. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. Jean Sommadossi currently is a Senior Advisor to PureTech Ventures. Jean Sommadossi was recently named to the Therapeutics Advisory Council of Harvard Medical School.
Follow Jean Sommadossi:
About Atea Pharmaceuticals, Idenix Pharmaceuticals: Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Sangeeta Bhatia
Co-Founder of Satellite Bio
Sangeeta Bhatia is Wilson Professor of Engineering, MIT.
Follow Sangeeta Bhatia:
About Broad Institute, Harvard Stem Cell Institute, Massachusetts Institute of Technology, Satellite Bio: Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.
Robert Coffin
Founder and CEO of Replimune Group
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Follow Robert Coffin:
About Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Philip Sparke
Founder of Replimune Group
He also acted as the company’s Chairman from November 2009 until March 2011, when the company was acquired by Amgen for up to $1bn ($425m upfront). BioVex (now a subsidiary of Amgen) is based in Woburn, MA, USA and Abingdon, UK and develops biologics for solid tumours and prophylactic vaccines for infectious diseases. The Company’s lead program is completing Phase III testing for metastatic melanoma (study fully enrolled). Philip’s key responsibilities and achievements at Biovex include the successfully implemented exit strategy; the sale to Amgen represented one of the largest takeovers of a private VC backed biotech company in recent years. In 2005, Philip established Biovex’ US operations from scratch; recruiting the entire US senior management team (outside the CTO) whilst setting up all key functions including commercial capabilities. Arriving as the first employee in the US he grew the Company to 70 employees in Woburn, MA while retaining 30 in Abingdon, UK. Over the years, Philip executed five major private equity financings involving blue chip international investor syndicates totaling more than $160m including the second largest biotech VC raise of 2009 at $70m. He also oversaw the building of a launch grade manufacturing facility to zero default timelines and led his team through the agreement of a SPA with the FDA on the design of a pivotal study which commenced and was recruited on projected timeframes. Philip recently joined the Board of Directors of Oxyrane as Chairman.
Follow Philip Sparke:
About Elevate Investments, Forbion Capital Partners, Replimune Group, Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Christopher Wilfong
Chief Operating Officer and Co-Founder of Kronos Bio
Chris co-founded Kronos Bio in 2017 and currently serves as COO. Additionally, he is an Operating Partner at Two River, where he has co-founded and held interim management roles in several Two River portfolio companies including Kite Pharma, Inc. (acquired by Gilead), Nile Therapeutics, Inc. (acquired by Capricor Therapeutics), and Neogene Therapeutics. Prior to Two River, Chris was a Director and led the US investment team at Trustbridge Partners, a healthcare and technology-focused growth equity firm based in China. Prior to that, he was a Consultant at Bain & Company. Chris received his Master of Business Administration from the MIT Sloan School of Management, and his Bachelor of Science in Economics from the Wharton School of the University of Pennsylvania.
Follow Christopher Wilfong:
About 76Bio, Kronos Bio: Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer.
Jonathan Zhao
Co-Founder and Chairman of Hangzhou Just Biotherapeutics (Just China)
Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), PhD. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
Follow Jonathan Zhao:
About Hangzhou Just Biotherapeutics (Just China), Transcenta: Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Glenn Robertelli
Co-Founder & Chief Operating Officer of Admetsys
Follow Glenn Robertelli:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Robert Millman
Founder of CoStim Pharmaceuticals
Robert Millman brings to MPM 20 years of experience in creating and managing intellectual property and patent estates for biotechnology and drug discovery and development companies. Prior to joining MPM Capital, he was the Chief IP Counsel for Alnylam Pharmaceuticals Inc., where he developed the leading intellectual property portfolio in RNAi therapeutics. Prior to Alnylam, for three years he served as the Chief IP Counsel at Infinity Pharmaceuticals, Inc., a company focused on small molecule discovery. From 1999 to 2002, Mr. Millman was Chief IP Counsel at Celera Genomics, where he developed and implemented an IP protection plan during the race to sequence the human genome. Mr. Millman has previously served as Patent Counsel at Millennium Pharmaceuticals, Inc., and earlier in his career; he held an associate position at Morrison and Foerster LLP and a patent agent/specialist position at Sterne, Kessler Goldstein and Fox, LLP. Mr. Millman received his J.D. degree from the Washington College of Law at The American University, an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.
Follow Robert Millman:
About CoStim Pharmaceuticals: CoStim Pharmaceuticals Inc. operates as a biotechnology company. It develops antibody agents for treatment of cancer. The company was
Daphne Zohar
Founder, CEO of PureTech Health
Daphne Zohar is the founder and managing partner of PureTech, a technology development company tackling tomorrow’s biggest healthcare challenges. Ms. Zohar was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years, and by the Boston Globe as one of the “Top 15 Innovators.” A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Akili Interactive Labs, Vedanta Bioscience, Mandara Sciences, Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.
Follow Daphne Zohar:
About PureTech Health: PureTech Health is a bio pharma company and pushes the boundaries of medicine and changing and converging healthcare ecosystem.
Luk Vandenberghe
Co-Founder of GenSight Biologics
Follow Luk Vandenberghe:
About Affinia Therapeutics, Akouos, Broad Institute, GenSight Biologics, Grousbeck Gene Therapy Center, Harvard Medical School, Harvard University, Massachusetts Eye and Ear Infirmly: GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Maria Rupnick
Co-Founder of Larimar Therapeutics
Dr. Maria Rupnick M.D. is the Larimar Therapeutics’ Founder. She is a Cardiologist at Brigham and Women’s Hospital and an instructor of medicine at Harvard Medical School. Dr. Rupnick Co-Founded ZafGen, Inc. and served as its Member of the Scientific Advisory Board. She leads a research program focused on the control of tissue remodeling, particularly pathways that coordinate vascular and tissue responses. Her Long-term applications of her research also include new therapeutic targets for cardiac remodeling in heart failure. She co-founded Zafgen Inc. She serves as a Member of the Advisory Board of Zafgen Inc. Her work has received numerous awards, including the American Heart Association Katz Award. Dr. Rupnick received a Ph.D. in physiology/cell biology from Thomas Jefferson University and an M.D. from Harvard Medical School. She completed her postdoctoral training at MIT in biomedical engineering and residency/fellowship training at Brigham and Women’s Hospital.
Follow Maria Rupnick:
About Larimar Therapeutics: Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Shawn Marcell
Co-Founder, President & CEO of Torus Biosystems
Follow Shawn Marcell:
About Torus Biosystems: Torus Biosystems is a biotech startup that delivers molecular diagnostics for infectious diseases.
Zeel Patel
Co-Founder of Evera
Zeel Patel is the co-founder of EveraLabs.
Follow Zeel Patel:
About Evera: Evera is a stem cell banking company that allows the world to invest in their future health and wellbeing.
Mehmet Toner
Founder of Torpedo Diagnostics
Mehmet Toner is the Helen Andrus Benedict Professor of Bioengineering at the Massachusetts General Hospital, Harvard Medical School, and Harvard-MIT Health Sciences & Technology. He is internationally recognized for his research at the interface of nanotechnology, microsystems engineering, microfluidics, and applications in clinical medicine. Dr. Toner was born in Istanbul, Turkey. He obtained his undergraduate degree in mechanical engineering at the Istanbul Technical University, and his master’s degree and doctorate in Mechanical Engineering at MIT. He is the author of more than 300 original scientific and technical publications, and an inventor on more than 30 patents. Dr. Toner is a pioneer in the development of technologies to isolate extremely rare cells from blood, including circulating tumor cells. He is the founding Director of the NIH BioMicroElectroMechanical Systems Center, a nationwide center exploring the applications of microfluidics and nanotechnology in clinical medicine and life sciences. His work in cancer was awarded the Quantum grant from NIH as part of the “moon shot” program. His work has resulted in the formation of multiple companies servicing clinical diagnostics and biotechnology.
Follow Mehmet Toner:
About Massachusetts General Hospital, Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Ravi Kapur
Founder of Torpedo Diagnostics
Ravi Kapur is a scientist, engineer, and entrepreneur with 20 years of experience in developing and commercializing nascent technologies from academic laboratories. He is an Entrepreneur-in-Residence and directs the Innovation Team at Massachusetts General Hospital in Boston. He led the engineering team at MGH in development of the CTC-iChip. He has co-founded and built successful companies with innovative technology from MGH, MIT, Princeton, and Carnegie Mellon. He is currently the CEO of MicroMedicine Inc., a spinout from MGH. Dr. Kapur trained as a Bioengineer at Clemson University and cut his teeth in technology and product development at the United States Naval Research Laboratory in Washington DC.
Follow Ravi Kapur:
About Massachusetts General Hospital, Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Shyamala Maheswaran
Founder of Torpedo Diagnostics
Shyamala Maheswaran is an Associate Professor in Surgery at Harvard Medical School and the Scientific Director for the Center for Cancer Risk Assessment at the Massachusetts General Hospital. She is an authority in breast cancer biology and in molecular biology. Her long-term interest in the field of cancer biology has led to her leadership of collaborations with physicians, scientists and engineers, focused on the molecular applications of the CTC-iChip technology. Dr. Maheswaran graduated from the University of Peradeniya in Sri Lanka and received her doctorate in Biochemistry and Molecular Biology from Boston University, MA. Her research includes several high profile publications ranked in the top 1% of the academic field of Molecular Biology and Genetics based on a highly cited threshold for the field and publication year.
Follow Shyamala Maheswaran:
About Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Daniel Haber
Founder of Torpedo Diagnostics
Daniel Haber is the Director of Massachusetts General Hospital (MGH) Cancer Center, the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute (HHMI). He earned his BS and MS degrees from Massachusetts Institute of Technology (MIT), and his MD and PhD from Stanford. He completed his residency in internal medicine at MGH, his clinical fellowship in oncology at Dana Farber Cancer Institute, and his postdoctoral training at MIT, before joining the MGH faculty in 1991. Dr. Haber is known for his research in cancer genetics, including the discovery of genes implicated in the pediatric kidney cancer Wilms Tumor, the prevalence of founder BRCA mutations in young women of Ashkenazi descent. In 2004, his laboratory identified specific mutations in the epidermal growth factor receptor (EGFR) gene that underlie exquisite sensitivity to targeted kinase inhibitors, a milestone in the development of precision oncology targeting genetically-identified subsets of common epithelial cancers. The MGH Cancer Center now conducts a broad range of first-in-human clinical trials of targeted anti-cancer agents. Dr. Haber’s research is currently focused on the use of circulating tumor cells (CTCs) as a non-invasive “liquid biopsy” to detect and interrogate cancer cells at different stages of treatment response and disease progression, a project for which he and his close collaborator Dr. Mehmet Toner were awarded a Stand Up To Cancer Dream Team Award. Dr. Haber is a member of the National Academy of Medicine (Institute of Medicine), the American Academy of Arts and Science (AAAS), the Association of American Physicians (AAP), and the American Society for Clinical Investigation (ASCI).
Follow Daniel Haber:
About Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Chris Mason
Founder & Chief Scientific Officer of Avrobio
Chris Mason is the Founder & Chief Scientific Officer at AVROBIO .
Follow Chris Mason:
About Avrobio, Cell & Gene Therapy, Krystal Biotech, Ori Biotech, University College London (UCL): Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Geoff MacKay
Founder, President & CEO of Avrobio
Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.
Follow Geoff MacKay:
About Atlas Venture, Avrobio: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Jeffrey Medin
Scientific Founder of Avrobio
Jeffrey received his PhD in Biochemistry from the University of Kentucky. He then trained at the NIH working on gene transcription and gene transfer/therapy. He was recently a Senior Scientist at the University Health Network and a Full Professor at the University of Toronto. In January 2016, Jeffrey started a new position as the MACC Fund Endowed Professor in the Department of Pediatrics at the Medical College of Wisconsin in Milwaukee. He is also Vice Chair of Research Innovation for the Department of Pediatrics, Research Director within the Section of Pediatric Hematology/Oncology, and GMP Facility Director.
Follow Jeffrey Medin:
About Association of Pediatric Hematology/Oncology Nurses, Avrobio, GMP Securities, Medical College of Wisconsin: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Christopher Paige
Scientific Founder of Avrobio
Christopher earned a PhD in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland in 1980 where he worked until joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Christopher became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1997, he returned to OCI, now part of the University Health Network, to assume the role of Vice President, Research at UHN. Christopher is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.
Follow Christopher Paige:
About Avrobio, University of Toronto: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
David Hallal
CEO, Chair, & Co-Founder of ElevateBio
David Hallal, Chairman and CEO of ElevateBio, is a 30-year veteran in the biopharmaceutical industry, with expertise in early-stage company building as well as operating large multinational biotech companies. He also is Chairman and CEO of AlloVir, an ElevateBio portfolio company. Previously, David spent more than a decade at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the Chief Executive Officer of Alexion, David transitioned the company from a single-product to a multi-product enterprise. This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate, Ultomiris, from a preclinical stage to registration trials in multiple diseases in just 18 months. Prior to his appointment as CEO, David served as Alexion’s Chief Commercial Officer and then Chief Operating Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David has also held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. David serves as the Chairman of Scholar Rock (Nasdaq: SRRK), Chairman of iTeos Therapeutics, and is an independent director of Seer Biosciences. David is also an executive partner at MPM Capital. He holds a BA in psychology from the University of New Hampshire.
Follow David Hallal:
About Basecamp Bio, ElevateBio, Enobia Pharma: ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
Elisabet de los Pinos
Founder and CEO of Aura Biosciences
Follow Elisabet de los Pinos:
About Aura Biosciences: Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Robin Smith
Founder & CEO of ORIG3N
Robin Y Smith is the Founder and CEO of ORIG3N, a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases and DNA testing solutions for Health and Wellness. Visit: www.orig3n.com
Follow Robin Smith:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Kate Blanchard
Chief Operating Officer / Founder of ORIG3N
Follow Kate Blanchard:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Jeffrey D. Wager
Co-Founder, Chairman & CEO of EnBiotix
Follow Jeffrey D. Wager:
About EnBiotix, Proterris: EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Rudolf Jaenisch
Co-Founder of Fate Therapeutics
Rudolf Jaenisch is a founding member of the Whitehead Institute and a pioneer of developmental biology. He was the first to create a transgenic mouse, a technical achievement that changed the course of biomedical research by enabling the creation of animal models of human diseases. Dr. Jaenisch was also one of the first scientists to reprogram fully mature adult cells, like a skin cell, to become stem-like. Called induced pluripotent stem cells (iPSCs), this technology removed the dependence on embryos as a source of stem cells. At the Whitehead Institute, Dr. Jaenisch has been pursuing an understanding of epigenetic regulation and reprogramming, which has lead him to make principal discoveries in the field of stem cells. Dr. Jaenisch has coauthored more than 300 research papers, was appointed to the National Academy of Sciences and has received numerous prizes and recognitions, including First Peter Gruber Foundation Award in Genetics (2001), Robert Koch Prize for Excellence in Scientific Achievement (2002), BrupbacherFoundation Cancer Award (2003), Vilcek Prize (2007), and Massry Prize (2008).
Follow Rudolf Jaenisch:
About Fate Therapeutics, Fulcrum Therapeutics: Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Murali Aravamudan
Founder & Chief Executive Officer of Qrativ
Murali Aravamudan is Co-Founder and CEO of nference. Aravamudan was originally a researcher at Bell Labs, and helped build the first VoIP softswitch, which was deployed at Level3 and other companies. During the last boom, his first company, Winphoria, built a push-to-talk technology that competed with [Nextel](http://www.crunchbase.com/organization/nextel)’s. It was adopted by [Sprint](http://www.crunchbase.com/organization/sprint-nextel) and Verizon. The company raised $52 million, and was sold to [Motorola](http://www.crunchbase.com/organization/motorola) for $190 million in 2003.
Follow Murali Aravamudan:
About Anumana, nference, Qrativ: Qrativ is a developer of a drug purposing platform designed to reinvent the way treatments for diseases with unmet medical.
Robert Langer
Co-Founder of 480 Biomedical
Robert Langer is the David H.Koch Institute Professor at the Massachusetts Institute of Technology (MIT) (being an Institute Professor is the highest honor that can be awarded to a faculty member). Robert has written over 1,100 articles. Robert also has approximately 760 issued and pending patents worldwide.Robert’s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies. Robert served as a Member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest Advisory Board, from 1995 to 2002 and as its Chairman of the Board of Directors from 1999 to 2002. Robert has received over 180 major awards, including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s most prestigious technology prize. Robert is also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Robert has received are the Dickson Prize for Science (2002); the Heinz Award for Technology, Economy and Employment (2003); the Harvey Prize (2003); the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright); the General Motors Kettering Prize for Cancer Research (2004); the Dan David Prize in Materials Science (2005); the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research; induction into the National Inventors Hall of Fame (2006); the Max Planck Research Award (2008); and the Prince of Asturias Award for Technical and Scientific Research (2008). In 1998, Robert received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.” In 1989 Robert was elected to the Institute of Medicine of the National Academy of Sciences and in 1992 he was elected to both the National Academy of Engineering and the National Academy of Sciences. Robert is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction. Forbes magazine (1999) and Bio World (1990) have named Robert as one of the 25 most important individuals in biotechnology in the world. Discover magazine (2002) named him as one of the 20 most important people in this area. Forbes magazine (2002) selected Robert as one of the 15 innovators worldwide who will reinvent our future. Time magazine and CNN (2001) named Robert as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best). Parade magazine (2004) selected Robert as one of six “Heroes whose research may save your life.” Robert has received honorary doctorates from Harvard University, the Mt. Sinai School of Medicine, Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), Rensselaer Polytechnic Institute, Willamette University, the University of Liverpool (England), the University of Nottingham (England), Albany Medical College, Pennsylvania State University, Northwestern University, and Uppsala University (Sweden), and he received the University of California–San Francisco Medal. Robert urrently serves as a Member of the Board of Directors of Advanced Cell Technology and previously served as a Member of the Board of Directors at Momenta Pharmaceuticals from 2001 to 2009, Wyeth from 2004 to 2009, Fibrocell Science, Inc. from 2010 to 2012 and Millipore Corp from 2009 to 2010. Robert received his Bachelor’s Degree from Cornell University in 1970 and his ScD from the Massachusetts Institute of Technology in 1974, both in chemical engineering.
Follow Robert Langer:
About 3D-Matrix Medical Inc., 480 Biomedical, Arsenal Medical, Arsia Therapeutics, BIND Therapeutics, Entrega Bio, Kala Pharmaceuticals, Living Proof, LyfeBulb, Lyra Therapeutics, Massachusetts Institute of Technology, Moderna Therapeutics, PixarBio, Seer, Suono Bio, Teal Bio, TISSIUM, Verseau Therapeutics: 480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
Rajesh Devraj
CSO & Co-Founder of Disarm Therapeutics
Follow Rajesh Devraj:
About Atlas Venture, Disarm Therapeutics, Rectify Pharmaceuticals: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Edmund Sybertz
Founder of Lysosomal Therapeutics
Ted Sybertz, Ph.D., held various research leadership positions at Schering Plough, Geltex and Genzyme, focusing on cardiovascular and CNS diseases. At Genzyme, he played a leadership role in discovery and preclinical development of the glucosyl ceramide synthesis inhibitor, eliglustat. He has been associated with the discovery and introduction of over 20 molecules into clinical development, six of which were ultimately approved.
Follow Edmund Sybertz:
About Lysosomal Therapeutics: Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
Ronald A. DePinho
Co-Founder & Co-Chair of Asylia Therapeutics
Ronald DePinho is the Co-Founder and Co-Chair of Asylia Therapeutics.
Follow Ronald A. DePinho:
About Asylia Therapeutics, Karyopharm Therapeutics, Metamark Genetics, National Academy of Sciences, Nirogy Therapeutics, Stellanova Therapeutics, The University of Texas M.D. Anderson Cancer Center: Asylia Therapeutics is a biotech company focused on novel immune-modulating therapies for autoimmune, cancer, and infectious diseases.
Derrick Rossi
Founder of Intellia Therapeutics
In 2010, Dr. Rossi discovered a groundbreaking method to reprogram skin cells into stem cells utilizing messenger molecules. His novel technique eliminated the risk of cancer posed by previous methods and sparked a push to develop cellular and molecular therapeutic products using the technologies he developed. More recently, Dr. Rossi and colleagues again innovated in the stem cell field by applying the CRISPR/Cas9 system to generate hematopoietic stem cells resistant to HIV infection. Dr. Rossi continues to study CRISPR for application in human therapeutics.
Follow Derrick Rossi:
About Convelo Therapeutics, Intellia Therapeutics, Moderna Therapeutics, Stelexis Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Rodolphe Barrangou
Co-Founder of Intellia Therapeutics
Rodolphe Barrangou is an Associate Professor of Food, Bioprocessing and Nutrition Sciences at North Carolina State University. His lab focuses on the biology and genetics of CRISPR/Cas immune systems in bacteria. He also serves on the Board of Directors of Caribou Biosciences. Rodolphe was previously a Director of Research and Development at DuPont and Danisco. While with Dansico, he was part of the team that initially established the adaptive immune function of CRISPR systems. Rodolphe received his PhD in Functional Genomics from North Carolina State University and an MBA from the University of Wisconsin, Madison.
Follow Rodolphe Barrangou:
About Intellia Therapeutics, North Carolina State University – NCSU: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Luciano Marraffini
Founder & Advisor of Intellia Therapeutics
Luciano Marraffini is an Assistant Professor of Bacteriology at Rockefeller University. Luciano’s laboratory investigates the underlying molecular mechanisms of CRISPR immunity, and seeks to employ this natural pathway to develop new technologies. He is a 2012 Rita Allen Foundation Scholar and the recipient of a 2012 NIH Director’s New Innovator Award. Luciano received his PhD from the University of Chicago where he studied bacterial pathogenesis, and completed his postdoctoral fellowship at Northwestern University.
Follow Luciano Marraffini:
About Eligo Bioscience, Intellia Therapeutics, The Rockefeller University: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Andrew Clark
Co-Founder and Chief Scientific Officer of Camallergy
Andy has been a consultant in paediatric allergy at Addenbrooke’s Hospital since 2003, gaining his MD Thesis in Allergy in the same year. He runs the paediatric allergy service at Addenbrooke’s and this work is complemented by a broad UK Government-funded research portfolio. In 2010 Andy was named in ‘The Times’ magazine list of top UK doctors, and again in 2012 he was recognised as one of the UK’s 100 best children’s specialist doctors. He plays an active role in the national parent allergy organisation (BSACI) as chair of the standards of care committee. He recently led writing guideline documents for managing egg allergy and in 2012 he was appointed chair of this committee. He now coordinates the writing of guidelines on multiple topics, such as peanut, milk and penicillin allergy, and adrenaline auto-injector use. Andy is also secretary to the taskforce on the allergic child in school, which produced European guidelines for school allergy and he is Chair of the expert scientific panel of the Anaphylaxis Campaign. Andy lectures frequently to undergraduates, primary and secondary care doctors and nurses and is a regular invited speaker at national and European allergy conferences.
Follow Andrew Clark:
About Camallergy, University of Cambridge: Camallergy develops and provides new treatments for common food allergies.
Andrew Miller
Founder & COO of Karuna Therapeutics
Dr. Miller is a Founder, Director, and the Chief Operating Officer of Karuna Pharmaceuticals. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston. Previously, Dr. Miller was a Vice President at PureTech Health for 8 years, most recently as Vice President, the COO of Tal Medical, and the acting-COO of Entrega where he serves on the board. Dr. Miller completed his doctoral work in Chemical Engineering at the Massachusetts Institute of Technology and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. Dr. Miller received a B.S. in Chemical Engineering from the University of Illinois with highest honors.
Follow Andrew Miller:
About Karuna Therapeutics, Tal Medical: Karuna Therapeutics is a Massachusetts-based developer of drugs for the treatment of schizophrenia.
Feng Zhang
Co-Founder of Arbor Biotechnologies
Feng Zhang joined the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard as a core member in 2011. Dr. Zhang is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is now working to extend this molecular engineering approach to other aspects of brain function, such as gene expression, and to develop new approaches to understanding and eventually treating brain diseases. Dr. Zhang is a Searle Scholar and has received both a Director’s Transformative Research Award and a Directors’ Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics. Feng Zhang a Co-Founder at Arbor Biotechnologies. Dr. Zhang holds an A.B. in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.
Follow Feng Zhang:
About Arbor Biotechnologies, Beam Therapeutics, Editas Medicine, Massachusetts Institute of Technology, Massachusetts Institute of Technology, Massachusetts Institute of Technology, Sherlock Biosciences: Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
David R. Walt
Co-Founder of Arbor Biotechnologies
David is Professor in the Department of Pathology, Brigham and Women’s Hospital and Wyss Institute for Biologically Inspired Engineering, and is a Howard Hughes Medical Institute Professor. David is the Scientific Founder of Illumina Inc. and Quanterix Corp and has co-founded several other life sciences startups. David has published over 300 peer-reviewed papers and has over 75 issued US patents. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules including the American Chemical Society Kathryn C. Hach Award for Entrepreneurial Success, Ralph Adams Award in Bioanalytical Chemistry, the American Chemical Society Gustavus John Esselen Award, Analytical Chemistry Spectrochemical Analysis Award, the Pittsburgh Analytical Chemistry Award, and the ACS National Award for Creative Invention. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He received a BS in Chemistry from the University of Michigan and a PhD in Chemical Biology from SUNY at Stony Brook, and did postdoctoral studies at MIT.
Follow David R. Walt:
About Arbor Biotechnologies, Illumina, Quanterix, Sherlock Biosciences, Torus Biosystems, Ultivue: Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Winston Yan
Co-Founder of Arbor Biotechnologies
Winston is a biotechnologist discovering and developing applications for novel molecular technologies. Prior to co-founding Arbor, Winston worked in the laboratory of Feng Zhang at MIT and the Broad Institute, where he focused on addressing challenges that limit the in vivo therapeutic applications of CRISPR-Cas nucleases. This included developing smaller orthologs of Cas9 for better packaging into the most therapeutically promising viral vectors for gene therapy, building assays that enhance off-target detection to evaluate the genomic safety of CRISPR-Cas enzymes, and additionally searching for new enzyme systems to power genome engineering capabilities beyond nucleases. Winston graduated magna cum laude with a BS in Physics from Harvard College, and PhD in Biophysics from Harvard University as a part of the Harvard-MIT MD/PhD program. Recognition for his research and entrepreneurship has included the Sir Peter Mansfield Research Fellowship, Herchel Smith Undergraduate Research Fellowship, Olken Brothers’ Award for Entrepreneurial Spirit, Harvard I3 Innovation Challenge Winner, Micron Science & Technology Scholarship Top Awardee, and the Paul & Daisy Soros Fellowship.
Follow Winston Yan:
About Arbor Biotechnologies: Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
David Scott
Co-Founder, Head of Innovation of Arbor Biotechnologies
David works at the intersection of computer science and biology, leveraging emerging data streams to create exciting new biotechnologies. Prior to co-founding Arbor, David completed his PhD in the laboratory of Feng Zhang at MIT and the Broad Institute, where he contributed to the early development of CRISPR-Cas systems for mammalian genome editing applications. As part of this work, David created experimental and computational techniques to enhance the precision of CRISPR-Cas applications and discover novel CRISPR gene editing systems. David is the recipient of the National Science Foundation Graduate Research Fellowship, the Henry E. Singleton Fellowship, and the Angus MacDonald Award for Excellence in Undergraduate Teaching. He received his BS in Cognitive Science from the University of California San Diego, where he co-authored several research studies illuminating the early progression of Alzheimer’s and Parkinson’s diseases.
Follow David Scott:
About Arbor Biotechnologies: Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
David Berry
Founder and CEO of Valo Health
David Berry, M.D., PhD., is an American inventor, entrepreneur, venture capitalist and CEO. Berry has co-founded and helped build over 10 companies in life sciences, technology, and sustainability. In 2007, he was named as the Innovator of the Year from the MIT Technology Review TR35 list of one of the top 35 innovators in the world under the age of 35. He was selected as a 2014 Young Global Leader by the World Economic Forum. In 2007, Berry founded Joule Unlimited, which is developing Solar Fuels—drop-in fuels produced directly from the sun. Berry served as President and CEO of the company through April 2009, and currently serves on the Board of Directors. Joule is pioneering solar fuels through a new technology that coverts sunlight, carbon dioxide, and salt water into drop-in fuels for prices as low as $20. In March 2010 and again in March 2011, Joule was named by Technology Review as one of the 50 Most Innovative Companies. Joule was named as one of the 10 most important emerging technologies in 2011. Joule’s unique and innovative approach to fuels led to its being named a Technology Pioneer by the World Economic Forum in 2012 and to its receiving the Silver Medal in the 2011 Wall Street Journal Technology Innovation Awards. Joule’s technology has now been successfully scaled to a demonstration facility, and the company has announced a commercial partnership with Audi. Berry has been recognized multiple times as one of the top people in bioenergy by Biofuels Digest. In 2009, Berry founded Pronutria, which is pioneering a new approach to unlock the vast untapped therapeutic potential of proteins in the diet. Berry served as President and CEO through March 2012. Pronutria has built a proprietary database that contains over 1 billion food proteins, and leverages 40 years of clinical data that validates the pharmacological activity of particular amino acid combinations to identify proteins that, when delivered orally, act as prodrugs. The protein delivery form allows for of important drug-like properties including pharmacokinetic control and improvement of physiochemical features. Pronutria has advanced two of its ProNutrein™ into clinical trials. In 2011, Berry founded Seres Health, a company that develops a new class of therapeutics based on insights into the biology of the human microbiome. Seres Health has developed a new approach to functionally assess the changes of the microbiome associated with disease, and identifies a consortia of organisms that can catalyze a shift to health. Seres has advanced is lead into the clinic for recurrent C. difficile. In 2005, Berry co-founded LS9, with Chris Somerville, Jay Keasling, and George M. Church, which uses synthetic biology to engineer microorganisms to covert sustainable, plant-based materials into low-carbon fuels and chemicals. LS9 has successfully built on technologies he invented with other co-founders to produce a scalable platform for renewable fules and chemicals. This technology was successfully scaled to a fully operational 135,000L facility in Okeechobee, Florida. The impact and importance of LS9’s technology led to its being named a Technology Pioneer by the World Economic Forum in 2008 and its being awarded the Presidential Green Chemistry Challenge Award in 2010, the U.S. Environmental Protection Agency’s highest environmental honor. LS9 was acquired by Renewable Energy Group in 2014. Berry joined Flagship Ventures, a Cambridge, Massachusetts based venture capital firm that invests in and founds companies in healthcare and sustainability, in 2005 where he is a Partner. Berry has been described “a rising star of the Boston-area venture capital scene,” and “one of the most brilliant thinkers.” Berry serves on the Board of Directors of Joule Unlimited, Seres Health, Pronutria, Eleven Biotherapeutics (NASDAQ: EBIO), and Symbiota. Berry has been an author of 14 scientific papers and over 60 patent applications.
Follow David Berry:
About Axcella, Evelo Biosciences, Flagship Pioneering, Hackley School, Indigo, Joule Unlimited Technologies, Omega Therapeutics, Seres Therapeutics, Seres Therapeutics, Valo Health: Valo Health uses human-centric data and machine learning-anchored computation to transform the drug discovery and development process.
David Sabatini
Founder of KSQ Therapeutics
David Sabatini is a Member of the Whitehead Institute for Biomedical Research, and he is Senior Associate Member at the Broad Institute, Member of the Koch Institute for Integrative Cancer Research, and a Professor of Biology, all with the Massachusetts Institute of Technology (MIT). He is also a Howard Hughes Medical Institute Investigator. David and his lab at the Whitehead Institute study the basic mechanisms that regulate growth, the processes whereby cells and organisms accumulate mass and increase in size, as well as the role of metabolism in cancer and in the mechanisms that control the effects of dietary restriction on tumorigenesis.
Follow David Sabatini:
About Broad Institute, KSQ Therapeutics, Navitor Pharmaceuticals, Raze Therapeutics, The Howard Hughes Medical Institute: KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.